General Information of Drug Combination (ID: DCEC3K1)

Drug Combination Name
SNX-2112 RTB101
Indication
Disease Entry Status REF
Ovarian endometrioid adenocarcinoma Investigative [1]
Component Drugs SNX-2112   DMB5A80 RTB101   DM62QTW
Small molecular drug Small molecular drug
High-throughput Screening Result Testing Cell Line: A2780
Zero Interaction Potency (ZIP) Score: 6.03
Bliss Independence Score: 5.59
Loewe Additivity Score: 5.78
LHighest Single Agent (HSA) Score: 9.74

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of SNX-2112
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
SNX-2112 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Heat shock protein 90 alpha (HSP90A) TT78R5H HS90A_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
SNX-2112 Interacts with 14 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK) OTLF4ZB1 IKKA_HUMAN Decreases Expression [5]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [5]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [5]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Decreases Expression [5]
Endoplasmin (HSP90B1) OT02XLBR ENPL_HUMAN Decreases Expression [5]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [5]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Expression [5]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Expression [5]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [5]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Expression [5]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [5]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [5]
Heat shock protein 75 kDa, mitochondrial (TRAP1) OTNG0L8J TRAP1_HUMAN Decreases Expression [5]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DOT(s)
Indication(s) of RTB101
Disease Entry ICD 11 Status REF
Respiratory tract infection CA45 Phase 3 [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
RTB101 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
CREB-regulated transcription coactivator 1 (TORC1) TT4GO0F CRTC1_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour DC24OZ1 ES2 Investigative [7]
Breast and ovarian cancer syndrome DC3JG56 UWB1289+BRCA1 Investigative [8]
Breast carcinoma DC2RGU3 OCUBM Investigative [8]
Carcinoma DC801JN OV90 Investigative [8]
Carcinoma DCCLDRK MDAMB436 Investigative [8]
Colon adenocarcinoma DCQFSS3 LOVO Investigative [8]
Colon carcinoma DCCQX5B RKO Investigative [8]
Invasive ductal carcinoma DC0FJPG T-47D Investigative [8]
Rectal adenocarcinoma DC4TXJD SW837 Investigative [8]
Adenocarcinoma DCLUOV9 CAOV3 Investigative [1]
Adenocarcinoma DCO48A5 A427 Investigative [1]
Adenocarcinoma DCKUWNC NCIH1650 Investigative [1]
Adenocarcinoma DCHYKY9 NCIH2122 Investigative [1]
Adenocarcinoma DCKCJYE NCIH520 Investigative [1]
Adenocarcinoma DCA1EJW DLD1 Investigative [1]
Adenocarcinoma DCBBXWJ HCT116 Investigative [1]
Adenocarcinoma DC5D886 HT29 Investigative [1]
Adenocarcinoma DC7KLTO SW-620 Investigative [1]
Amelanotic melanoma DC0OURA A2058 Investigative [1]
Germ cell tumour DCXS1QQ PA1 Investigative [1]
Large cell lung carcinoma DCQ0USO NCI-H460 Investigative [1]
Malignant melanoma DCPHVNA A375 Investigative [1]
Malignant melanoma DCNOMJ4 HT144 Investigative [1]
Malignant melanoma DCBJX51 RPMI7951 Investigative [1]
Malignant melanoma DC7881Q SKMEL30 Investigative [1]
Malignant melanoma DC65VHH UACC62 Investigative [1]
Mesothelioma DCASNR4 MSTO Investigative [1]
Non small cell carcinoma DCER53Z SKMES1 Investigative [1]
Ovarian serous cystadenocarcinoma DC9HIBF SK-OV-3 Investigative [1]
Prostate carcinoma DCMSZZQ LNCAP Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 30 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010 Jan 14;53(1):3-17.
3 ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health.
5 The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-B and disruption of mitochondria-dependent pathways. Chem Biol Interact. 2013 Sep 5;205(1):1-10. doi: 10.1016/j.cbi.2013.06.007. Epub 2013 Jun 15.
6 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
7 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
8 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.